Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Zepbound approved for treating moderate to severe obstructive sleep apnea in adults with obesity, showing improvement in ...

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

As part of a new campaign, Whitley is partnering with Zepbound to break down the stigma surrounding obesity and inspire others to seek support and treatment.